Gain Therapeutics, Inc.
GANX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001819411
No open-market purchases or sales by Gain Therapeutics, Inc. insiders were filed in the last 90 days; 50 institutions reported holding it in 13F filings for Q2 2026, worth $17.4M in total; Greenlight Capital is the only superinvestor holding it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +8 vs. previous quarter
- 50
- 13F valueReported value at the end of Q2 2026
- $17.4M
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding GANX, Q2 2026
1 superinvestor reports holding Gain Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Greenlight Capital
David Einhorn
<0.1%
Gain Therapeutics, Inc.'s share of the portfolio
- Shares
- 566,130
- Value
- $1.15M
Latest insider trades
Open-market purchases and sales by Gain Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 12, 2024 (view filing) | Aug 9 | 3 days | Mack GeneCFO and Interim CEO | PPurchase | +14.4K | $1.01 | +$14.5K | New position14.4K after | |
| Aug 12, 2024 (view filing) | Aug 9 | 3 days | Islam KhalidExecutive Chairman | PPurchase | +50.0K | $1.00 | +$50.0K | New position50.0K after | |
| Jul 1, 2024 (view filing) | Jul 1 | Same day | Richman Eric IDirector | PPurchase | +17.0K | $1.22 | +$20.7K | +6.2%289.6K after | 2 lots |
| Apr 1, 2024 (view filing) | Mar 28 | 4 days | Riley Jeffrey ScottDirector | PPurchase | +30.0K | $3.86 | +$115.8K | New position30.0K after | |
| Dec 22, 2023 (view filing) | Dec 21 | 1 day | Alder MatthiasChief Executive Officer | SSale | −206 | $2.46 | −$506.76 | −3.8%5.29K after | |
| Dec 14, 2023 (view filing) | Dec 7 | 7 daysLate | Alder MatthiasChief Executive Officer | SSale | −1.82K | $2.50 | −$4.55K | −27.3%4.86K after | |
| May 27, 2022 (view filing) | May 25 | 2 days | Richman Eric ICHIEF EXECUTIVE OFFICER | PPurchase | +2.48K | $2.58 | +$6.40K | +1.2%217.7K after | |
| May 23, 2022 (view filing) | May 19 | 4 days | Richman Eric ICHIEF EXECUTIVE OFFICER | PPurchase | +4.00K | $2.71 | +$10.8K | +2.0%206.0K after | |
| May 23, 2022 (view filing) | May 20 | 3 days | Richman Eric ICHIEF EXECUTIVE OFFICER | PPurchase | +9.26K | $2.83 | +$26.2K | +4.5%215.2K after | |
| May 23, 2022 (view filing) | May 19 | 4 days | Calabrese SalvatoreCHIEF FINANCIAL OFFICER | PPurchase | +3.00K | $2.70 | +$8.10K | New position3.00K after | Amended |
Top 10 13F holders, Q2 2026
The largest institutional positions in Gain Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Marshall Wace, LLP | 1,923,546 | $3.90M | 0.00% | +153,758+8.7% | Added |
| Potomac Capital Management, Inc. | 946,400 | $1.92M | 1.41% | −62,200−6.2% | Reduced |
| Gsa Capital Partners LLP | 632,131 | $1.28M | 0.08% | +319,664+102.3% | Added |
| Cambridge Investment Research Advisors, Inc. | 568,645 | $1.15M | 0.00% | 00.0% | Unchanged |
| DME Capital Management, LPSuperinvestorGreenlight Capital | 566,130 | $1.15M | 0.03% | 00.0% | Unchanged |
| Jones Financial Companies LLLP | 608,592 | $1.07M | 0.00% | −23,023−3.6% | Reduced |
| Vanguard Capital Management LLC | 480,269 | $974.9K | 0.00% | +80,383+20.1% | Added |
| Geode Capital Management, LLC | 453,501 | $921.4K | 0.00% | +6,159+1.4% | Added |
| BlackRock, Inc. | 274,957 | $558.2K | 0.00% | +49,911+22.2% | Added |
| Vanguard Fiduciary Trust Co | 231,534 | $470.0K | 0.00% | +1,555+0.7% | Added |